歌禮制藥(01672.HK):成功獲得藥品經營許可證和GSP證書,形成完整商業化佈局
格隆匯獲悉,歌禮制藥(01672.HK),一家致力於解決抗病毒、癌症及脂肪肝疾病三大領域中尚未被滿足醫療需求的研發驅動型創新生物科技公司,於2019年11月29日宣佈,歌禮旗下全資子公司歌禮欣諾醫藥(杭州)有限公司(下稱“歌禮欣諾”)於近日獲得浙江省藥品監督管理局頒發的《藥品經營許可證》和《藥品經營質量管理規範認證證書》(簡稱藥品GSP證書)。
歌禮欣諾為集藥品經銷、進出口、代理為一體的藥品經營企業,主要經營歌禮旗下生產企業及合作方的各類創新藥品。歌禮欣諾完善的GSP質量管理體系和現代化物流設施設備,確保創新藥產品在流通過程的質量控制。
歌禮創始人、董事長兼首席執行官吳勁梓博士表示:“歌禮已發展成為一體化平台型公司,完成了從新藥發現和開發、生產到商業化的創新藥全產業鏈的佈局。歌禮獲得藥品經營資質,標誌着商業化佈局的又一里程碑,助力歌禮成為新藥創制行業全產業鏈充分合作的最佳夥伴。”
未來,歌禮將通過歌禮欣諾引進全球範圍內潛力創新藥產品,豐富創新藥物產品線;同時通過歌禮欣諾佈局“一帶一路”新藥科技創新國際合作,將歌禮的全球新(first-in-class)產品惠及“一帶一路”沿線國家及地區患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.